New depression pill shows promise in large trial
NCT ID NCT04984512
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called mitizodone phosphate in 600 adults with major depression. The goal is to see if it reduces depression symptoms better than a placebo over 8 weeks. The trial has two phases: first to find the best dose, then to confirm how well it works and if it's safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEPRESSIVE DISORDER, MAJOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sunshine Lake Pharma Co., Ltd.
RECRUITINGDongguan, Guangdong, 523871, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a single dose of a new drug boost depression relief?
- Can a new pill ease depression without Add-Ons?
- Brain scans could make TMS for depression more precise
- Can brain training help depressed young adults stop ruminating?
- 45,000 students to be tracked: can we predict who will fall into depression?
- New depression pill BI 1569912 put to the test in 225-Person trial